(firstQuint)A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Ibrutinib in Healthy Participants.

 This is a single-center, open-label (all people know the identity of the intervention), sequential design study in healthy men.

 All participants will receive ibrutinib on Day 1 and ibrutinib in combination with ketoconazole on Day 7.

 Food will be restricted from the evening before dosing until 4 hours after dosing on Days 1 and 7.

 Following an overnight fast, ketoconazole will be given on Days 4 to 6, 1 hour prior to ibrutinib dosing on Day 7, and again on Days 8 and 9.

 All ibrutinib and ketoconazole doses will be administered with water.

 The participants will leave the study center on Day 10.

.

 A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Ibrutinib in Healthy Participants@highlight

The purpose of this study is to assess the potential effects of ketoconazole on the pharmacokinetics of ibrutinib in healthy participants.

